Browse drugs

… with CHE. Other independent associated factors were non-use of mineralocorticoid receptor antagonists before admission (aOR 4.1, 95% CI 1.5 to 11.1), reduced left ve…

…in TRED-HF received angiotensin receptor–neprilysin inhibitors (ARNIs) or SGLT2 inhibitors, compared with 61% and 63% of TRED-HF2 pat…

… (40%). In patients with reduced LVEF, the prescription rate of ACE inhibitors, angiotensin receptor blockers or angiotensin receptor-neprilys…

…the consolidation of four foundational pharmacological pillars: beta-blockers, renin-angiotensin system inhibitors or angiotensin receptor-ne…

…ient, with ICERs generally below willingness-to-pay thresholds. Dapagliflozin was cost saving in type 2 diabetes (T2D) in the United Kingdom …

… kidney disease progression by 24% [HR 0.76; 95% CI 0.67–0.87]. Canagliflozin reduced the composite renal outcome [HR 0.66; 95% CI 0.53–0.81]…

…d kidney complications, independent of blood pressure. Although mineralocorticoid receptor antagonists (MRAs) are the standard treatment when surgical adrenalectomy i…

…Background The role of mineralocorticoid receptor antagonists (MRAs) in acute myocardial infarction (MI) remains controversia…

…iated during follow-up—may still exist. At baseline, the use of sodium–glucose cotransporter 2 inhibitors, mineralocorticoid receptor antagonists, and glucagon-like pept…

…inhibitors or angiotensin receptor-neprilysin inhibitor (ARNI), beta-blockers, mineralocorticoid receptor antagonists (MRA) and sodium-glucos…

…erences showed both regional similarities and differences, with SGLT2 inhibitors being the most preferred drug of choice universally. In contras…